Goodwin assisted Metagenomi on the matter. Preclinical biotech Metagenomi went public on the Nasdaq under the ticker “MGX”, raising $94 million by offering 6.25 million shares...
Metagenomi’s $94 Million Initial Public Offering
C4 Therapeutics’ Exclusive Licensing Agreement with Betta Pharmaceuticals
Goodwin Procter served as legal counsel to C4T, and Han Kun Law Offices served as legal counsel to Betta. C4 Therapeutics, Inc. announced its exclusive licensing agreement...
Acrivon Therapeutics’ $99.4 Million Initial Public Offering
Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...
Rapid Micro Biosystems’ $158.4 Million IPO
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
Valneva SE’s $107.6 Million Global Offering
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Hogan Lovells and Cooley advised Valneva. Gide advised Goldman Sachs, Jefferies,...
LumiraDx Limited’s Merger Agreement with CA Healthcare Acquisition
Goodwin Procter, Fried Frank and Appleby advised LumiraDx Limited on the deal, while Sidley Austin LLP acted for CA Healthcare Acquisition Corp. LumiraDx Limited announced its...